Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Etelcalcetide (Parsabiv) vs Pegvisomant (Somavert)
An educational, source-based comparison of Etelcalcetide (Parsabiv) and Pegvisomant (Somavert) — how each peptide works, what it's researched for, and what to know before going deeper.
Calcimimetic peptide for secondary hyperparathyroidism on hemodialysis.
Synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells, increasing its sensitivity to extracellular calcium and lowering PTH secretion.
- Secondary hyperparathyroidism in adults on chronic hemodialysis
- • FDA-approved.
- • Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
Pegylated GH receptor antagonist for acromegaly.
Genetically engineered analog of human GH with site-directed mutations blocking functional dimerization of the GH receptor; pegylation extends half-life. Lowers IGF-1 without lowering GH.
- Acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs
- • FDA-approved.
- • Monitor LFTs; tumor monitoring via MRI required.
- • Lipohypertrophy at injection sites.
Etelcalcetide (Parsabiv) vs Pegvisomant (Somavert) — Key differences
- Class: Etelcalcetide (Parsabiv) is classified as Calcium-Sensing Receptor Agonist · Endocrine, while Pegvisomant (Somavert) is GH Receptor Antagonist · Endocrine.
- Primary research focus: Etelcalcetide (Parsabiv) — secondary hyperparathyroidism in adults on chronic hemodialysis; Pegvisomant (Somavert) — acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Endocrine.